Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.

By R. Azziz, D. Ehrmann, R. Legro, R. Whitcomb, R. Hanley, A. G. Fereshetian, Mary O’Keefe, M. Ghazzi. Journal of Clinical Endocrinology and Metabolism, 2001

594 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Public Health, Environmental and Occupational Health, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/7d9057cb75df4a0c8835ff6db97d77689393bf5b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Public Health, Environmental and Occupational Health

In Reproductive Medicine

Citations in the corpus

Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline (2013, background): “Women with PCOS had a monthly spontaneous ovulation rate of 32% on placebo in a multicenter trial that randomly assigned subjects to placebo or troglitazone (69).”
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). (2004, methodology): “Currently there are scant data to indicate that markers of insulin resistance predict responses to treatment (Moghetti et al., 2000; Imani et al., 2000; Azziz et al., 2001).”
Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. (2006, unknown): “ofwomenwithPCOSwhoparticipatedinalargemulticenter national trial ( 14 ).”
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. (2009, background): “Contrast this with a recent multicenter trial at 22 sites in the United States in PCOS, where the BMI in the four treatment arms (total n 1⁄4 305) ranged from 35 to 38 kg/ m(2) (219).”